klow peptide what is it peptide klow peptide 80mg KLOW Blend 80mg BPC-157/TB-500/KPV/GHK-Cu -

RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer

No suprime la produccion endogena de hormonas y no requiere terapia post-ciclo (PCT)

Here is the crux of the article, stated as plainly as possible: there are no published, controlled human clinical trials establishing a skin or cosmetic benefit from injected (subcutaneous) GHK-Cu

Significant reduction in melanin index is seen usually after 10 weeks

Injection burden 12 injections most days Best for Independent dose control Cycle driver Compound-specific phasing BPC-157 Loading 250500 mcg, daily Frequency Daily Maintenance 250 mcg, daily Route SubQ TB-500 Loading 2.05.0 mg, 2x/week Frequency 2x/week (loading), 12x/week (maintenance) Maintenance 2.0 mg, 12x/week Route SubQ Example Weekly Schedule (Loading Phase) Monday BPC-157 500 mcg SubQ + TB-500 2.5 mg SubQ Tuesday BPC-157 500 mcg SubQ Wednesday BPC-157 500 mcg SubQ Thursday BPC-157 500 mcg SubQ + TB-500 2.5 mg SubQ Friday BPC-157 500 mcg SubQ Saturday BPC-157 500 mcg SubQ Sunday BPC-157 500 mcg SubQ Use separate sterile syringes for separate-vial draws

doi:10.1016/j.biochi.2020.04.004 Araki R, Maruyama C, Igarashi S, et al